Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$451.73 USD
-9.52 (-2.06%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $450.51 -1.22 (-0.27%) 6:42 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALNY 451.73 -9.52(-2.06%)
Will ALNY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock?
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
Other News for ALNY
ALNY Stock: B of A Securities Raises Price Target to $520 | ALNY Stock News
Calm After Storm appears for ALNY after 0.02% move
Alnylam price target raised to $520 from $453 at BofA
Alnylam price target raised by $67 at BofA, here's why
Alnylam Pharma: Promising Growth Driven by ATTR-CM Franchise and siRNA Platform Expansion